<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03539575</url>
  </required_header>
  <id_info>
    <org_study_id>1308012514A</org_study_id>
    <secondary_id>1R21DA041580-01A1</secondary_id>
    <nct_id>NCT03539575</nct_id>
  </id_info>
  <brief_title>CB1R in Synthetic Psychoactive Cannabinoids</brief_title>
  <acronym>CB1R in Spice</acronym>
  <official_title>CB1R Availability in Synthetic Psychoactive Cannabinoid Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether the CB1R availability is lower in
      synthetic psychoactive cannabinoid subjects using the most widely available synthetic
      psychoactive cannabinoids at the time the study is initiated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positron Emission Tomography (PET Imaging)</measure>
    <time_frame>Change in CB1R availability from baseline throughout one test day</time_frame>
    <description>CB1R availability using [11-C]OMAR PET imaging Change in CB1R availability (e.g. volume distribution).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CogState Battery</measure>
    <time_frame>Change in CB1R availability from baseline throughout one test day</time_frame>
    <description>2. Changes in Cognition during withdrawal using a computerized battery Changes in cognitive functions such as attention, memory, motor functioning, and processing speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroencephalogram</measure>
    <time_frame>Change in CB1R availability from baseline throughout one test day</time_frame>
    <description>3. Changes in brain rhythms measured by Electroencephalography Changes in electroencephalographic (EEG) brain rhythms related to information processing.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Drug Dependence</condition>
  <arm_group>
    <arm_group_label>Synthetic Psychoactive Cannabinoid Users</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Synthetic Psychoactive Cannabinoid dependent subjects who are frequent spice/K2 users will receive the radiotracer [11-C]OMAR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[11-C]OMAR</intervention_name>
    <description>The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.</description>
    <arm_group_label>Synthetic Psychoactive Cannabinoid Users</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Able to provide written consent

          -  Age 18-55

          -  Current Synthetic Psychoactive Cannabinoids consumption

        Exclusion:

          -  MRI metal exclusions and claustrophobia

          -  Education completed is less than 12 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak C D'Souza, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohini Ranganathan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick D Skosnik, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deepak C D'Souza, M.D.</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>2594</phone_ext>
    <email>deepak.dsouza@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick Skosnik, Ph.D.</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>2252</phone_ext>
    <email>patrick.skosnik@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mackenzie Griffin, B.S.</last_name>
      <phone>203-974-7775</phone>
      <email>mackenzie.griffin@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberlee Bielen, B.S.</last_name>
      <phone>203-974-7540</phone>
      <email>kimberlee.forselius@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deepak C D'Souza, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohini Ranganathan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick D Skosnik, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>May 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>K2</keyword>
  <keyword>Spice</keyword>
  <keyword>Synthetic Marijuana</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

